Copyright Reports & Markets. All rights reserved.

Global (United States, European Union and China) Passive Transdermal Drug Delivery Market Research Report 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Research Scope
    • 1.2 Major Manufacturers Covered in This Report
    • 1.3 Market Segment by Type
      • 1.3.1 Global Passive Transdermal Drug Delivery Market Size Growth Rate by Type (2019-2025)
      • 1.3.2 Microfluidics
      • 1.3.3 Smart Pill Technology (SPT)
    • 1.4 Market Segment by Application
      • 1.4.1 Global Passive Transdermal Drug Delivery Market Share by Application (2019-2025)
      • 1.4.2 Clinic
      • 1.4.3 Hospital
      • 1.4.4 Others
    • 1.5 Study Objectives
    • 1.6 Years Considered

    2 Global Growth Trends

    • 2.1 Production and Capacity Analysis
      • 2.1.1 Global Passive Transdermal Drug Delivery Production Value 2014-2025
      • 2.1.2 Global Passive Transdermal Drug Delivery Production 2014-2025
      • 2.1.3 Global Passive Transdermal Drug Delivery Capacity 2014-2025
      • 2.1.4 Global Passive Transdermal Drug Delivery Marketing Pricing and Trends
    • 2.2 Key Producers Growth Rate (CAGR) 2019-2025
      • 2.2.1 Global Passive Transdermal Drug Delivery Market Size CAGR of Key Regions
      • 2.2.2 Global Passive Transdermal Drug Delivery Market Share of Key Regions
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers

    3 Market Share by Manufacturers

    • 3.1 Capacity and Production by Manufacturers
      • 3.1.1 Global Passive Transdermal Drug Delivery Capacity by Manufacturers
      • 3.1.2 Global Passive Transdermal Drug Delivery Production by Manufacturers
    • 3.2 Revenue by Manufacturers
      • 3.2.1 Passive Transdermal Drug Delivery Revenue by Manufacturers (2014-2019)
      • 3.2.2 Passive Transdermal Drug Delivery Revenue Share by Manufacturers (2014-2019)
      • 3.2.3 Global Passive Transdermal Drug Delivery Market Concentration Ratio (CR5 and HHI)
    • 3.3 Passive Transdermal Drug Delivery Price by Manufacturers
    • 3.4 Key Manufacturers Passive Transdermal Drug Delivery Plants/Factories Distribution and Area Served
    • 3.5 Date of Key Manufacturers Enter into Passive Transdermal Drug Delivery Market
    • 3.6 Key Manufacturers Passive Transdermal Drug Delivery Product Offered
    • 3.7 Mergers & Acquisitions, Expansion Plans

    4 Market Size by Type

    • 4.1 Production and Production Value for Each Type
      • 4.1.1 Microfluidics Production and Production Value (2014-2019)
      • 4.1.2 Smart Pill Technology (SPT) Production and Production Value (2014-2019)
    • 4.2 Global Passive Transdermal Drug Delivery Production Market Share by Type
    • 4.3 Global Passive Transdermal Drug Delivery Production Value Market Share by Type
    • 4.4 Passive Transdermal Drug Delivery Ex-factory Price by Type

    5 Market Size by Application

    • 5.1 Overview
    • 5.2 Global Passive Transdermal Drug Delivery Consumption by Application

    6 Production by Regions

    • 6.1 Global Passive Transdermal Drug Delivery Production (History Data) by Regions 2014-2019
    • 6.2 Global Passive Transdermal Drug Delivery Production Value (History Data) by Regions
    • 6.3 United States
      • 6.3.1 United States Passive Transdermal Drug Delivery Production Growth Rate 2014-2019
      • 6.3.2 United States Passive Transdermal Drug Delivery Production Value Growth Rate 2014-2019
      • 6.3.3 Key Players in United States
      • 6.3.4 United States Passive Transdermal Drug Delivery Import & Export
    • 6.4 European Union
      • 6.4.1 European Union Passive Transdermal Drug Delivery Production Growth Rate 2014-2019
      • 6.4.2 European Union Passive Transdermal Drug Delivery Production Value Growth Rate 2014-2019
      • 6.4.3 Key Players in European Union
      • 6.4.4 European Union Passive Transdermal Drug Delivery Import & Export
    • 6.5 China
      • 6.5.1 China Passive Transdermal Drug Delivery Production Growth Rate 2014-2019
      • 6.5.2 China Passive Transdermal Drug Delivery Production Value Growth Rate 2014-2019
      • 6.5.3 Key Players in China
      • 6.5.4 China Passive Transdermal Drug Delivery Import & Export
    • 6.6 Rest of World
      • 6.6.1 Japan
      • 6.6.2 Korea
      • 6.6.3 India
      • 6.6.4 Southeast Asia

    7 Passive Transdermal Drug Delivery Consumption by Regions

    • 7.1 Global Passive Transdermal Drug Delivery Consumption (History Data) by Regions
    • 7.2 United States
      • 7.2.1 United States Passive Transdermal Drug Delivery Consumption by Type
      • 7.2.2 United States Passive Transdermal Drug Delivery Consumption by Application
    • 7.3 European Union
      • 7.3.1 European Union Passive Transdermal Drug Delivery Consumption by Type
      • 7.3.2 European Union Passive Transdermal Drug Delivery Consumption by Application
    • 7.4 China
      • 7.4.1 China Passive Transdermal Drug Delivery Consumption by Type
      • 7.4.2 China Passive Transdermal Drug Delivery Consumption by Application
    • 7.5 Rest of World
      • 7.5.1 Rest of World Passive Transdermal Drug Delivery Consumption by Type
      • 7.5.2 Rest of World Passive Transdermal Drug Delivery Consumption by Application
      • 7.5.1 Japan
      • 7.5.2 Korea
      • 7.5.3 India
      • 7.5.4 Southeast Asia

    8 Company Profiles

    • 8.1 3M
      • 8.1.1 3M Company Details
      • 8.1.2 Company Description and Business Overview
      • 8.1.3 Production and Revenue of Passive Transdermal Drug Delivery
      • 8.1.4 Passive Transdermal Drug Delivery Product Introduction
      • 8.1.5 3M Recent Development
    • 8.2 Actavis, Inc.
      • 8.2.1 Actavis, Inc. Company Details
      • 8.2.2 Company Description and Business Overview
      • 8.2.3 Production and Revenue of Passive Transdermal Drug Delivery
      • 8.2.4 Passive Transdermal Drug Delivery Product Introduction
      • 8.2.5 Actavis, Inc. Recent Development
    • 8.3 Bayer AG
      • 8.3.1 Bayer AG Company Details
      • 8.3.2 Company Description and Business Overview
      • 8.3.3 Production and Revenue of Passive Transdermal Drug Delivery
      • 8.3.4 Passive Transdermal Drug Delivery Product Introduction
      • 8.3.5 Bayer AG Recent Development
    • 8.4 Boehringer Ingelheim GmbH
      • 8.4.1 Boehringer Ingelheim GmbH Company Details
      • 8.4.2 Company Description and Business Overview
      • 8.4.3 Production and Revenue of Passive Transdermal Drug Delivery
      • 8.4.4 Passive Transdermal Drug Delivery Product Introduction
      • 8.4.5 Boehringer Ingelheim GmbH Recent Development
    • 8.5 Corium International, Inc.
      • 8.5.1 Corium International, Inc. Company Details
      • 8.5.2 Company Description and Business Overview
      • 8.5.3 Production and Revenue of Passive Transdermal Drug Delivery
      • 8.5.4 Passive Transdermal Drug Delivery Product Introduction
      • 8.5.5 Corium International, Inc. Recent Development
    • 8.6 Echo Therapeutics, Inc.
      • 8.6.1 Echo Therapeutics, Inc. Company Details
      • 8.6.2 Company Description and Business Overview
      • 8.6.3 Production and Revenue of Passive Transdermal Drug Delivery
      • 8.6.4 Passive Transdermal Drug Delivery Product Introduction
      • 8.6.5 Echo Therapeutics, Inc. Recent Development
    • 8.7 GlaxoSmithKline plc
      • 8.7.1 GlaxoSmithKline plc Company Details
      • 8.7.2 Company Description and Business Overview
      • 8.7.3 Production and Revenue of Passive Transdermal Drug Delivery
      • 8.7.4 Passive Transdermal Drug Delivery Product Introduction
      • 8.7.5 GlaxoSmithKline plc Recent Development
    • 8.8 Johnson & Johnson (Janssen Pharmaceuticals Inc.)
      • 8.8.1 Johnson & Johnson (Janssen Pharmaceuticals Inc.) Company Details
      • 8.8.2 Company Description and Business Overview
      • 8.8.3 Production and Revenue of Passive Transdermal Drug Delivery
      • 8.8.4 Passive Transdermal Drug Delivery Product Introduction
      • 8.8.5 Johnson & Johnson (Janssen Pharmaceuticals Inc.) Recent Development
    • 8.9 Mylan N.V.
      • 8.9.1 Mylan N.V. Company Details
      • 8.9.2 Company Description and Business Overview
      • 8.9.3 Production and Revenue of Passive Transdermal Drug Delivery
      • 8.9.4 Passive Transdermal Drug Delivery Product Introduction
      • 8.9.5 Mylan N.V. Recent Development
    • 8.10 Novartis AG
      • 8.10.1 Novartis AG Company Details
      • 8.10.2 Company Description and Business Overview
      • 8.10.3 Production and Revenue of Passive Transdermal Drug Delivery
      • 8.10.4 Passive Transdermal Drug Delivery Product Introduction
      • 8.10.5 Novartis AG Recent Development
    • 8.11 Noven Pharmaceuticals, Inc.
    • 8.12 Transdermal Corp.

    9 Market Forecast

    • 9.1 Global Market Size Forecast
      • 9.1.1 Global Passive Transdermal Drug Delivery Capacity, Production Forecast 2019-2025
      • 9.1.2 Global Passive Transdermal Drug Delivery Production Value Forecast 2019-2025
    • 9.2 Market Forecast by Regions
      • 9.2.1 Global Passive Transdermal Drug Delivery Production and Value Forecast by Regions 2019-2025
      • 9.2.2 Global Passive Transdermal Drug Delivery Consumption Forecast by Regions 2019-2025
    • 9.3 United States
      • 9.3.1 Production and Value Forecast in United States
      • 9.3.2 Consumption Forecast in United States
    • 9.4 European Union
      • 9.4.1 Production and Value Forecast in European Union
      • 9.4.2 Consumption Forecast in European Union
    • 9.5 China
      • 9.5.1 Production and Value Forecast in China
      • 9.5.2 Consumption Forecast in China
    • 9.6 Rest of World
      • 9.6.1 Japan
      • 9.6.2 Korea
      • 9.6.3 India
      • 9.6.4 Southeast Asia
    • 9.7 Forecast by Type
      • 9.7.1 Global Passive Transdermal Drug Delivery Production Forecast by Type
      • 9.7.2 Global Passive Transdermal Drug Delivery Production Value Forecast by Type
    • 9.8 Consumption Forecast by Application

    10 Value Chain and Sales Channels Analysis

    • 10.1 Value Chain Analysis
    • 10.2 Sales Channels Analysis
      • 10.2.1 Passive Transdermal Drug Delivery Sales Channels
      • 10.2.2 Passive Transdermal Drug Delivery Distributors
    • 10.3 Passive Transdermal Drug Delivery Customers

    11 Opportunities & Challenges, Threat and Affecting Factors

    • 11.1 Market Opportunities
    • 11.2 Market Challenges
    • 11.3 Porter's Five Forces Analysis

    12 Key Findings

      13 Appendix

      • 13.1 Research Methodology
        • 13.1.1 Methodology/Research Approach
          • 13.1.1.1 Research Programs/Design
          • 13.1.1.2 Market Size Estimation
          • 13.1.1.3 Market Breakdown and Data Triangulation
        • 13.1.2 Data Source
          • 13.1.2.1 Secondary Sources
          • 13.1.2.2 Primary Sources
      • 13.2 Author Details

      In 2019, the market size of Passive Transdermal Drug Delivery is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period.
      In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Passive Transdermal Drug Delivery.

      This report studies the global market size of Passive Transdermal Drug Delivery, especially focuses on the key regions like United States, European Union, China, and other regions (Japan, Korea, India and Southeast Asia).
      This study presents the Passive Transdermal Drug Delivery production, revenue, market share and growth rate for each key company, and also covers the breakdown data (production, consumption, revenue and market share) by regions, type and applications. history breakdown data from 2014 to 2019, and forecast to 2025.
      For top companies in United States, European Union and China, this report investigates and analyzes the production, value, price, market share and growth rate for the top manufacturers, key data from 2014 to 2019.

      In global market, the following companies are covered:
      3M
      Actavis, Inc.
      Bayer AG
      Boehringer Ingelheim GmbH
      Corium International, Inc.
      Echo Therapeutics, Inc.
      GlaxoSmithKline plc
      Johnson & Johnson (Janssen Pharmaceuticals Inc.)
      Mylan N.V.
      Novartis AG
      Noven Pharmaceuticals, Inc.
      Transdermal Corp.

      Market Segment by Product Type
      Microfluidics
      Smart Pill Technology (SPT)

      Market Segment by Application
      Clinic
      Hospital
      Others

      Key Regions split in this report: breakdown data for each region.
      United States
      China
      European Union
      Rest of World (Japan, Korea, India and Southeast Asia)

      The study objectives are:
      To analyze and research the Passive Transdermal Drug Delivery status and future forecast in United States, European Union and China, involving sales, value (revenue), growth rate (CAGR), market share, historical and forecast.
      To present the key Passive Transdermal Drug Delivery manufacturers, presenting the sales, revenue, market share, and recent development for key players.
      To split the breakdown data by regions, type, companies and applications
      To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
      To identify significant trends, drivers, influence factors in global and regions
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market

      In this study, the years considered to estimate the market size of Passive Transdermal Drug Delivery are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025

      Buy now